Kramer R M, Sharp J D
Cardiovascular Research, Lilly Research Laboratories, Indianapolis, IN 46285, USA.
FEBS Lett. 1997 Jun 23;410(1):49-53. doi: 10.1016/s0014-5793(97)00322-0.
The 85-kDa cytosolic PLA2 (cPLA2) is present in many cells and tissues and its unusual functional properties and catalytic mechanism are being elucidated. Notably, cPLA2 becomes catalytically active in the presence of free Ca2+ concentrations as present in stimulated cells and preferentially cleaves arachidonic acid-containing phospholipids. A variety of agonists, growth factors and cytokines, as well as stressful stimuli activate cPLA2 to hydrolyze cellular phospholipids thereby liberating fatty acids and lysophospholipids and providing the precursor substrates for the biosynthesis of eicosanoids and platelet-activating factor. These products of cPLA2 contribute to inflammatory and degenerative disease states and cPLA2 is therefore an attractive target for the development of novel therapies.
85 kDa的胞质型磷脂酶A2(cPLA2)存在于许多细胞和组织中,其独特的功能特性和催化机制正在被阐明。值得注意的是,cPLA2在受刺激细胞中存在的游离Ca2+浓度下具有催化活性,并优先裂解含花生四烯酸的磷脂。多种激动剂、生长因子和细胞因子,以及应激刺激均可激活cPLA2,使其水解细胞磷脂,从而释放脂肪酸和溶血磷脂,并为类花生酸和血小板活化因子的生物合成提供前体底物。cPLA2的这些产物会导致炎症和退行性疾病状态,因此cPLA2是开发新型疗法的一个有吸引力的靶点。